

Cutaneous tolerance to long term anakinra therapy : report of a 9 year experience and review of french pharmacovigilance


M. Bonsergent¹, J. Giraud¹, R. Asgari², L. Deschamps³, S. Ottaviani⁴, C. Bejar⁵, T. Papo⁶, J.F Alexandra⁶, C. Tesmoingt¹

¹Department of Pharmacy, ³Department of Pathology, ⁴Department of Rheumatology, ⁵Department of Dermatology, ⁶Department of Internal Medicine, Hôpital Bichat-Claude Bernard, Paris, France, ²Regional Center of Pharmacovigilance, Hôpital Européen Georges-Pompidou, Paris, France.

Background : Anakinra, a recombinant human interleukin-1 receptor antagonist, is commonly used in the treatment of rheumatoid arthritis and also shown efficacy in some auto-inflammatory diseases. This drug is generally known for being well tolerated.

2 Objectives : - To explore cutaneous tolerance in patients who received a long-term anakinra treatment in our hospital
- To investigate the similar cases of adverse cutaneous reactions reported in the French pharmacovigilance database


Methods :



Results :



Two patients developed an acute onset of erythematous and very painful eruption localized in all injection sites in the same time which refers to a "recall syndrome"



Histology :
a) Parakeratosis, focal and superficial keratinocytes necrosis and lymphocytic exocytosis
b) Perivascular lymphocytic infiltrate in the dermis, without leukocytoclastic vasculitis

Criteria	Hospital research	French pharmacovigilance database
Median age (years)	47	43
Sex ratio (F/M)	3,5	2,7
Mean interval of appearance (days) [bounds]	7 [2-365]	25 [1-122]
Drug discontinuation	44 % (4/9)	70% (26/37)
Reintroduction	0	23% (6/26)
Reappearance of cutaneous reaction after rechallenging	NA	83% (5/6)

Clinical manifestations :

- Small inflammatory reaction on injection site
- Severe erythematous and edematous eruption
- Painful and pruriginous eruption
- Urticarial rashes on injection sites
- Exanthema
- Maculopapular rash
- Generalized urticaria
- Panniculitis on the 4 limbs
- Eczematous and pruritic eruption
- Inflammatory plaques
- Psoriasis eruption

Conclusion :

This study was the first to describe the real life tolerance of anakinra over a 9 years period in a wide spectrum of diseases. Our series highlighted an important rate of major side effects (69%) leading to treatment discontinuation. This may be of major concern as anakinra is usually used as rescue treatment for auto-inflammatory diseases.